Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 59 publications
Low-Dose Interleukin-2 Enhances Activated Suppressor Regulatory T Cells and CTLA-4 and HLA-DR Expression in Chronic Chikungunya Arthritis.
Journal: Pathogens (Basel, Switzerland)
Published: June 17, 2026
Do women with HIV, diabetes mellitus, and full antiretroviral therapy adherence have a lower rate of HIV viremia than men?
Journal: AIDS (London, England)
Published: September 10, 2024
The Natural History of Post-Chikungunya Viral Arthritis Disease Activity and T-cell Immunology: A Cohort Study.
Journal: Journal of cellular immunology
Published: June 14, 2024
Development of a Chikungunya Arthritis Disease Activity Score (CHIK-DAS) Based on a Prospective Cohort Study.
Journal: Journal of cellular immunology
Published: January 01, 2024
Evaluating the Role of the Renin-angiotensin System in COVID-19: Implications for ACE Inhibitor and ARB Use During SARS-CoV-2 Infection.
Journal: Journal of cellular immunology
Published: January 01, 2024
Dengue NS1 Antibodies Are Associated With Clearance of Viral Nonstructural Protein-1.
Journal: The Journal of infectious diseases
Published: November 21, 2023
Does Pneumocystis jirovecii pneumonia cause long-term deficits in lung function?
Journal: AIDS (London, England)
Published: November 06, 2023
Cytokine and T cell responses in post-chikungunya viral arthritis: A cross-sectional study.
Journal: PloS one
Published: October 05, 2023
Effects of IL2/anti-IL2 antibody complex on chikungunya virus-induced arthritis in a mouse model.
Journal: bioRxiv : the preprint server for biology
Published: February 13, 2023
Effects of rIL2/anti-IL2 antibody complex on chikungunya virus-induced chronic arthritis in a mouse model.
Journal: Scientific reports
Published: January 31, 2023
Regulatory T-cells and GARP expression are decreased in exercise-associated chikungunya viral arthritis flares.
Journal: Frontiers in immunology
Published: July 29, 2022
Cardiovascular disease (CVD) risk assessment of HIV medication regimens using hematopoietic CD34+ progenitor cells.
Journal: Stem cell research & therapy
Published: January 05, 2022
Last Updated: 09/26/2026